Brian T Hill
Overview
Explore the profile of Brian T Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
6491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
2.
Locke F, Siddiqi T, Jacobson C, Nikiforow S, Ahmed S, Miklos D, et al.
Blood Adv
. 2025 Jan;
PMID: 39883946
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR...
3.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
4.
Jain M, Spiegel J, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, et al.
J Clin Oncol
. 2024 Aug;
42(30):3581-3592.
PMID: 39094076
Purpose: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known...
5.
Choudhary G, Tat T, Misra S, Hill B, Smith M, Almasan A, et al.
Oncotarget
. 2024 Jul;
15:468-469.
PMID: 39007277
No abstract available.
6.
Lunning M, Wang H, Hu Z, Locke F, Siddiqi T, Jacobson C, et al.
Am J Hematol
. 2024 Mar;
99(5):880-889.
PMID: 38504387
Axicabtagene ciloleucel (axi-cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma...
7.
Hill B, Chen Y, Jagadeesh D, Dean R, Koc O, Boughan K, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):768-773.
PMID: 38456694
Lenalidomide and rituximab (R) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteasome inhibitor ixazomib...
8.
Locke F, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al.
Nat Med
. 2024 Jan;
30(2):507-518.
PMID: 38233586
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed...
9.
Jain M, Jacobs M, Gao F, Nastoupil L, Spiegel J, Lin Y, et al.
Blood Adv
. 2023 Dec;
8(4):1042-1050.
PMID: 38051550
During the manufacturing period of autologous chimeric antigen receptor (CAR) T-cell therapy, patients may experience a decline in their condition due to cancer progression. In this study, we investigated the...
10.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...